Regeneron hits Amgen over its blockbuster eye disease treatment

The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Regeneron edges closer to Eylea market exclusivity amid biosimilar threats

6 March 2025 New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows intense scrutiny during Federal Circuit oral arguments | Decision follows similar rulings against Samsung Bioepis and Formycon.

Americas

Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan

13 February 2025 The company’s Eylea treatment patent faced intense scrutiny as the US Federal Circuit heard Williams & Connolly, RMMS Legal, and McGuireWoods argue over criticality, stability, and validity.

Americas

Regeneron holds off copies of $6bn eye treatment

4 February 2025 Federal Circuit upholds preliminary injunctions blocking highly similar versions of Eylea | Samsung Biopeis and Formycon failed to convince that the patent-in-suit was invalid.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Regeneron hits Amgen over its blockbuster eye disease treatment

More on this story

Editor's picks

Editor's picks

More features